A study of four Ebola therapeutics demonstrated that two drugs showed significantly improved survival rates, leading to the trial being halted early.
Browsing: Emerging Disease
The outbreak of Ebola in the Democratic Republic of Congo has seen over 2612 cases and 1756 mortalities since it was first announced by the WHO on 1 August 2018. One year on we ask, what have the major milestones been of this outbreak? And where are we now; is there an end in sight?
The fourth International Health Regulations Emergency Committee meeting has concluded by declaring a Public Health Emergency of International Concern, following the recent Ebola virus disease outbreak in the Democratic Republic of the Congo.
In this interview we speak to Chikwe Ihekweazu, current Director of the Nigeria Centre for Disease Control, about monkeypox, public trust, surveillance and the factors that influence preparedness.
Take a look at this month’s industry headlines including an FDA approval for Zebraxa, new funding for chikungunya vaccine clinical…
In this interview we speak to Vineet Menachery about his recent talk at the Microbiology Society’s Annual Conference (8–11 April, Belfast, UK) suggesting that CoV emergence is more complicated than receptor binding alone.
Two years after Ebola infection, survivors exhibit specific memory T cell responses against ebolavirus, according to new research presented at ECCMID.
Take a look at this month’s industry headlines including news on Sanofi’s Dengvaxia® vaccine from the USA and the Philippines, clinical trial results for RSV vaccines and HIV injectables and new acquisitions for Merck.